Acute Coronary Syndrome (ACS) Clinical Trial
The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength,
maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in
platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A
study reported that the TEG® can be used as routine monitoring of the variability in ADP
receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay,
we could find out the perioperative clopidogrel responsiveness of the patients with ACS
undergoing OPCAB.
The purpose of this study is to determine whether the rate of the major adverse cardiac
events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in
the patients with high degree of clopidogrel resistance, who are scheduled to undergo the
OPCAB due to ACS.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00385138 -
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
|
Phase 3 | |
Completed |
NCT01944800 -
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT02290080 -
Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
|
Phase 3 | |
Completed |
NCT02286544 -
Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01405287 -
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
|
Phase 2 | |
Completed |
NCT00767507 -
Maintenance of Platelet Inhibition With Cangrelor
|
Phase 2 | |
Completed |
NCT03672097 -
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
Completed |
NCT00399880 -
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
|
N/A | |
Completed |
NCT02430493 -
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
|
N/A | |
Completed |
NCT01994577 -
Optimum Troponin Cutoffs for ACS in the ED
|
||
Completed |
NCT00313300 -
Safety Study of Apixaban in Recent Acute Coronary Syndrome
|
Phase 2 | |
Completed |
NCT02244710 -
EndoTic - Endothelium and Ticagrelor
|
N/A | |
Active, not recruiting |
NCT04090281 -
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
|
Phase 4 | |
Active, not recruiting |
NCT03581578 -
VITROS Immunodiagnostic Products hs Troponin I
|
||
Recruiting |
NCT04116931 -
OPTImal Management of Antithrombotic Agents: OPTIMA-5
|
Phase 4 | |
Not yet recruiting |
NCT06449274 -
RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial
|
N/A | |
Completed |
NCT02171065 -
PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
|
N/A | |
Completed |
NCT00855257 -
Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome
|
Phase 3 | |
Completed |
NCT02733341 -
The Effect of IV Cangrelor and Oral Ticagrelor Study
|
Phase 4 | |
Completed |
NCT00932100 -
A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
|
Phase 2 |